Biosciences announced preclinical results for its investigational compound BMB-201, in a validated isosorbide dinitrate rat ...

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated ...

36.2 x 120.6 x 120.6 cm. (14.3 x 47.5 x 47.5 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...

Bright Minds Biosciences Inc. has released preclinical results for BMB‑201, a selective 5-HT2A/2C receptor agonist, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 ...

• Robust efficacy versus vehicle at 1 and 2 hours in both sexes (periorbital von Frey thresholds). • Benchmark comparison: BMB‑201 showed greater effect sizes than sumatriptan at multiple timepoints ...